The primary objective of establishing safety and tolerability was achieved in both healthy adults (study C-001) and in adults with acute otitis media (study C-004).
Read More
The reason for the delay is that the Company has not completed its annual audited financial statements because it has not finalized certain entries, none of which is material to the Company’s financial condition.
Read More
The ACR CRISS score was the primary efficacy endpoint of the Phase 2 study evaluating lenabasum for the treatment of diffuse cutaneous SSc.
Read More
The company will hold a conference call on Thursday, May 30, 2019, at 5:00 pm ET following the release of its first quarter 2019 financial results after market close.
Read More
The company’s overall strategy is to discover, develop and commercialize novel therapeutics from its proprietary cannabinoid product platform.
Read More
Get stock alerts, news & related alerts straight to your inbox!